C4 Therapeutics, Inc. (CCCC)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue from collaboration agreements | 6,463 | 7,238 | 15,362 | 12,006 |
| Restructuring | - | - | - | - |
| Research and development | 26,197 | 27,072 | 31,838 | 23,753 |
| General and administrative | 8,767 | 9,330 | 11,768 | 9,695 |
| Total operating expenses | 34,964 | 36,402 | 43,606 | 33,448 |
| Loss from operations | -28,501 | -29,164 | -28,244 | -21,442 |
| Interest expense and amortization of long-term debt − related party | - | - | - | - |
| Interest and other income, net | 2,481 | 2,842 | 3,578 | 3,726 |
| Total other income, net | 2,481 | 2,842 | 3,578 | 3,726 |
| Loss before income taxes | -26,020 | -26,322 | -24,666 | -17,716 |
| Income tax expense | - | - | - | - |
| Net loss | -26,020 | -26,322 | -24,666 | -17,716 |
| Unrealized loss on marketable securities | -73 | -10 | 895 | -60 |
| Comprehensive loss | -26,093 | -26,332 | -23,771 | -17,776 |
| Net loss per share basic (in dollars per share) | -0.37 | -0.37 | -0.35 | -0.26 |
| Net loss per share diluted (in dollars per share) | -0.37 | -0.37 | -0.35 | -0.26 |
| Weighted-average number of shares used in computed net loss per share basic | 71,005,743 | 70,833,044 | 69,627,190 | 68,810,259 |
| Weighted-average number of shares used in computed net loss per share diluted | 71,005,743 | 70,833,044 | 69,627,190 | 68,810,259 |